INT31148

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1987
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 0.14
Pain Relevance 1.82

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Cck) extracellular region (Cck) DNA binding (Cck)
Anatomy Link Frequency
body 2
Cck (Mus musculus)
Pain Link Frequency Relevance Heat
Cholecystokinin 130 100.00 Very High Very High Very High
antagonist 21 100.00 Very High Very High Very High
Opioid 6 87.12 High High
Pain threshold 1 77.12 Quite High
antinociception 1 66.00 Quite High
cocaine 3 50.00 Quite Low
Pain 2 25.00 Low Low
nociceptor 1 25.00 Low Low
medulla 27 8.24 Low Low
Eae 13 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pain 2 77.12 Quite High
Targeted Disruption 2 63.72 Quite High
Aids-related Complex 5 5.00 Very Low Very Low Very Low
Body Weight 2 5.00 Very Low Very Low Very Low
Anxiety Disorder 2 5.00 Very Low Very Low Very Low
Sleep Disorders 1 5.00 Very Low Very Low Very Low
Ganglion Cysts 1 5.00 Very Low Very Low Very Low
Appetite Loss 1 5.00 Very Low Very Low Very Low
Peripheral Arterial Disease 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CONCLUSIONS: The high expression of the CCK gene in the brain can decrease body weight and increase plasma glucose.
Negative_regulation (decrease) of Gene_expression (expression) of CCK gene in body
1) Confidence 0.43 Published 2009 Journal Chin. Med. J. Section Body Doc Link 19781389 Disease Relevance 0.06 Pain Relevance 0
Devazepide (L364,718), a selective antagonist of CCKA receptors, effectively blocked the action of CCK8(s), but not that of CCK4(30-33) or SNF 9007 (phase I).
Negative_regulation (blocked) of Gene_expression (action) of CCK8 associated with antagonist
2) Confidence 0.43 Published 1994 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8113956 Disease Relevance 0 Pain Relevance 0.46
In mice, intraperitoneally injected chlordiazepoxide and proglumide, both of which are regarded as cholecystokinin (CCK) receptor antagonists in the peripheral tissues, dose-dependently inhibited the satiety induced by 200 ng of intracisternally administered CCK octapeptide (CCK8).
Negative_regulation (regarded) of Gene_expression (antagonists) of CCK associated with antagonist and cholecystokinin
3) Confidence 0.43 Published 1987 Journal Jpn. J. Pharmacol. Section Abstract Doc Link 2883334 Disease Relevance 0.08 Pain Relevance 0.41
In contrast, 3R[+]-N-[2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-benzodiazepin-3-yl ]-N'- [3-methyl-phenyl]urea (L365,260), a selective CCKB receptor antagonist, blocked the action of CCK4(30-33) and SNF 9007 (phase I), and also antagonized CCK8(s), though to a lesser degree.
Negative_regulation (blocked) of Gene_expression (antagonist) of CCK associated with antagonist
4) Confidence 0.41 Published 1994 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8113956 Disease Relevance 0 Pain Relevance 0.31
Experiment 2 Individual and combined administration of CCK receptor antagonists and CART(61-102)
Negative_regulation (administration) of Gene_expression (antagonists) of CCK associated with antagonist and cholecystokinin
5) Confidence 0.41 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2587474 Disease Relevance 0 Pain Relevance 0.18
Devazepide (L364,718), a selective antagonist of CCKA receptors, effectively blocked the action of CCK8(s), but not that of CCK4(30-33) or SNF 9007 (phase I).
Negative_regulation (blocked) of Gene_expression (action) of CCK4 associated with antagonist
6) Confidence 0.37 Published 1994 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8113956 Disease Relevance 0 Pain Relevance 0.46

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox